Veracyte, Inc.
VCYT
Pozycja w akcjach
#4229
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Cena akcji
$46.05
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$3.70B
Zmiana (1 dzień)
2.81%
Zmiana (1 rok)
32.51%
Kraj
US
Handel Veracyte, Inc. (VCYT)
Kategoria
Healthcare
Historia ceny akcji dla Veracyte, Inc. (VCYT)
Najwyższa cena zamknięcia: $44.47 dnia 2026-10-01
Najniższa cena zamknięcia: $12.82 dnia 2013-10-01
Najniższa cena zamknięcia: $12.82 dnia 2013-10-01
Historia cen akcji firmy Veracyte, Inc. od 2013 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | -2.90% |
| 2025 | 3.85% |
| 2024 | 55.02% |
| 2023 | 1.26% |
| 2022 | -33.63% |
| 2021 | -25.42% |
| 2020 | 88.25% |
| 2019 | 137.21% |
| 2018 | 87.23% |
| 2017 | -13.42% |
| 2016 | 5.54% |
| 2015 | -8.13% |
| 2014 | -43.76% |
| 2013 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $694.53 | 22.45% |
US
|
|
| $234.00 | 7.29% |
US
|
|
| $416.01 | 121.26% |
US
|
|
| $21.16 | 49.45% |
CN
|
|
| $177.93 | 21.98% |
US
|
